Computational selection and experimental validation of allosteric ribozymes that sense a specific sequence of human telomerase reverse transcriptase mRNAs as universal anticancer therapy agents

Nucleic Acid Therapeutics

Volumn 23, Issue 6, 2013, Pages 408-417

  Penchovsky, Robert ^a   Kostova, Gergana T ^a  

^a UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OLIGONUCLEOTIDE; RIBOZYME; TELOMERASE REVERSE TRANSCRIPTASE;

ALGORITHM; ALLOSTERISM; ARTICLE; BIOINFORMATICS; CANCER GENE THERAPY; COMPUTER ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ANALYSIS; GENETIC SELECTION; HUMAN; HUMAN CELL; MOLECULAR SENSOR; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RNA SEQUENCE; RNA STRUCTURE; VALIDATION STUDY;

ALLOSTERIC REGULATION; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DRUG DESIGN; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; RNA CLEAVAGE; RNA, CATALYTIC; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TELOMERASE;

EID: 84890373058     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0446     Document Type: Article

References (38)

1. AUBERT, G., and LANSDORP, P.M. (2008). Telomeres and aging. Physiol. Rev. 88, 557-579
2. BLACKBURN, E.H. (2005). Telomeres and telomerase: Their mechanisms of action and the effects of altering their functions. FEBS Lett. 579, 859-862
3. BLOUNT, K., PUSKARZ, I., PENCHOVSKY, R., and BREAKER, R. (2006). Development and application of a high-Throughput assay for glmS riboswitch activators. RNA Biol. 3, 77-81
4. GRUBER, A.R., LORENZ, R., BERNHART, S.H., NEUBOCK, R., and HOFACKER, I.L. (2008). The Vienna RNA websuite. Nucleic Acids Res. 36, W70-74
5. GUO, P., HAQUE, F., HALLAHAN, B., REIF, R., and LI, H. (2012). Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther. 22, 226-245
6. HANAHAN, D., and WEINBERG, R.A. (2000). The hallmarks of cancer. Cell 100, 5770
7. HARLEY, C.B. (2008). Telomerase and cancer therapeutics. Nat. Rev. Cancer 8, 167-179
8. HAYFLICK, L., and MOORHEAD, P.S. (1961). The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585-621
9. HENSON, J.D., NEUMANN, A.A., YEAGER, T.R., and REDDEL, R.R. (2002). Alternative lengthening of telomeres in mammalian cells. Oncogene 21, 598-610
10. HINDLE, K.S., KIRKPATRICK, K., and MOKBEL, K. (2002). Correspondence re: Seki et al., Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin. Cancer Res., 7: 1976-1981, 2001. Clin Cancer Res 8, 628-629
11. ITO, H., KYO, S., KANAYA, T., TAKAKURA, M., KOSHIDA, K., NAMIKI, M., and INOUE, M. (1998). Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin. Cancer Res. 4, 2807-2810
12. KLAUSER, B., and HARTIG, J.S. (2013). An engineered small RNA-mediated genetic switch based on a ribozyme expression platform. Nucleic Acids Res 41, 5542-5552
13. KONG, D.S., CARR, P.A., CHEN, L., ZHANG, S., and JACOBSON, J.M. (2007). Parallel gene synthesis in a microfluidic device. Nucleic Acids Res. 35, e61
14. MATHEWS, D.H., SABINA, J., ZUKER, M., and TURNER, D.H. (1999). Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 288, 911-940
15. MCCASKILL, J.S. (1990). The equilibrium partition function and base pair binding probabilities for RNA secondary structure. Biopolymers 29, 1105-1119
16. OKADA, G., WATANABE, H., OHTSUBO, K., MOURI, H., YAMAGUCHI, Y.,MOTOO, Y., and SAWABU, N. (2012).Multiple factors influencing the release of hTERT mRNA from pancreatic cancer cell lines in in vitro culture. Cell Biol. Int. 36, 545-553
17. OSBORNE, E.M., SCHAAK, J.E., and DEROSE, V.J. (2005). Characterization of a native hammerhead ribozyme derived from schistosomes. RNA 11, 187-196
18. PENCHOVSKY, R. (2012a). Engineering gene control circuits with allosteric ribozymes in human cells as a medicine of the future. In: Quality Assurance in Healthcare Service Delivery, Nursing and Personalized Medicine: Technologies and Processes. A. Lazakidou and A. Daskalaki, eds. (IGI Global), pp. 71-92
19. PENCHOVSKY, R. (2012b). Engineering integrated digital circuits with allosteric ribozymes for scaling up molecular computation and diagnostics. ACS Synth. Biol. 1, 471-482
20. PENCHOVSKY, R. (2013a). Computational Design and Biochemical Probing of Allosteric Ribozymes as Molecular Biosensors. Nat. Protoc In Press
21. PENCHOVSKY, R. (2013b). Computational design and biosensor applications of small molecule-sensing allosteric ribozymes. Biomacromolecules 14, 1240-1249
22. PENCHOVSKY, R. (2013c). Present and future RNA-based approaches to medical genomics. International Journal of Genomic Medicine In Press
23. PENCHOVSKY, R. (2013d). Programmable and automated bead-based microfluidics for versatile DNA microarrays under isothermal conditions. Lab Chip 13, 2370-2380
24. PENCHOVSKY, R., and BREAKER, R.R. (2005). Computational design and experimental validation of oligonucleotide-sensing allosteric ribozymes. Nat. Biotechnol. 23, 1424-1433
25. PENCHOVSKY, R., and STOILOVA, C.C. (2013). Riboswitchbased antibacterial drug discovery using high-Throughput screening methods. Expert Opin. Drug Discov. 8, 65-82
26. PHATAK, P., and BURGER, A.M. (2007). Telomerase and its potential for therapeutic intervention. Br. J. Pharmacol. 152, 1003-1011
27. PIGANEAU, N., THUILLIER, V., and FAMULOK, M. (2001). In vitro selection of allosteric ribozymes: Theory and experimental validation. J. Mol. Biol. 312, 1177-1190
28. POOLE, J.C., ANDREWS, L.G., and TOLLEFSBOL, T.O. (2001). Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 269, 1-12
29. QIAN, L., and WINFREE, E. (2011). A simple DNA gate motif for synthesizing large-scale circuits. J. R. Soc. Interface 8, 1281-1297
30. RANKIN, A.M., FALLER, D.V., and SPANJAARD, R.A. (2008). Telomerase inhibitors and 'T-oligo' as cancer therapeutics: Contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs 19, 329-338
31. SEKI, K., SUDA, T., AOYAGI, Y., SUGAWARA, S., NATSUI, M., MOTOYAMA, H., SHIRAI, Y., SEKINE, T., KAWAI, H., MITA, Y., et al. (2001). Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin. Cancer Res. 7, 1976-1981
32. SHAY, J.W., and KEITH, W.N. (2008). Targeting telomerase for cancer therapeutics. Br. J. Cancer 98, 677-683
33. SMOGORZEWSKA, A., and DE LANGE, T. (2004). Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem. 73, 177-208
34. TANG, J., and BREAKER, R.R. (1997). Rational design of allosteric ribozymes. Chem. Biol. 4, 453-459
35. TINSLEY, R.A., FURCHAK, J.R., and WALTER, N.G. (2007). Trans-Acting glmS catalytic riboswitch: Locked and loaded. RNA 13, 468-477
36. WAGURI, N., SUDA, T., NOMOTO, M., KAWAI, H., MITA, Y., KUROIWA, T., IGARASHI, M., KOBAYASHI, M., FUKUHARA, Y., and AOYAGI, Y. (2003). Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Clin. Cancer Res. 9, 3004-3011
37. WANG, R.C., SMOGORZEWSKA, A., and DE LANGE, T. (2004). Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 119, 355-368
38. YEN, L., SVENDSEN, J., LEE, J-S., GRAY, J.T., MAGNIER, M., BABA, T., D'AMATO, R.J., and MULLIGAN, R.C. (2004). Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 431, 471-476